Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- SP
- AU
- EE
Lists including Stephane
Work Experience
2023
Member Board of Directors (SaagHA SAS)
2023
Vice President International
2022
A San-Francisco based JV between Verily (Google Life Sciences) and Santen, harnessing the convergence of AI, microelectronics and scalable digital technologies to treat eye diseases.
2022
Active Member / Business Angel
2022
First European investment network of Business Angeles specialized in healthcare. ACTIVE INVESTOR & SUPPORTER : - A biotech company specialized in veterinary regenerative medicine that is leveraging the unique biological potential of neonatal stem cells to promote the harmonious healing of injuries or dampen inflammatory chronic diseases. - The all in one fertility platform - making the fertility journey effortless and empowering - being powered by AI, backed by science. - A biotech company with a unique approach in active personalized cancer immunotherapy, by harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens - Device company developing a unique patient monitoring solution, able to measure all vital signs, including blood pressure, in one device. - A regenerative medicine project that aims at developing breast regeneration solutions by 3D bioprinting for women who had mastectomy following breast cancer.
2019
Member of the Board of Advisors
2019
Seenel Imaging is dedicated to functional Neuroimaging technology. We launched in 2019 a breakthrough research device combining EEG & fNIRS further to 10 years of Academic research. Medelopt® is a wearable High Resolution NIRS/EEG device with unique features on the market.
2017 - 2022
Global Head, Surgical
2021 - 2022
Director, Surgical Devices EMEA
2017 - 2021
RESPONSABILITY : - Structure and develop an independent business-unit dedicated to surgical devices. - Support the integration of InnFocus Ltd. following its US$225m+ acquisition. - Build and develop a dedicated team to launch PRESERFLO MicroShunt across Europe. ACHIEVEMENT : - Established PRESERFLO MicroShunt as the preferred surgical option for advanced glaucoma patients' management. - Built & managed a dedicated team of Surgical Partners across Europe, with all necessary support functions (Medical Affairs, Market-Access, Marketing, Commercial Excellence). - Established the Surgical Division as the fastest-growing franchise (revenue & profit) within Santen.
Sr. Director, Business Expansion EMEA
2015 - 2016
** Covidien (ex- Tyco Healthcare), acquired by Medtronic in 2015 ** RESPONSABILITY : - Built the MITG Procedural Solutions Program & developed the franchise across EMEA. - Managed the MITG OEM Business-Unit. ACHIEVEMENT : - Established the Procedural Solution Offering for hernia, colorectal, bariatric and thoracic surgical procedures. - Commercial launch across 20+ countries (annuel revenue >US$50m).
Director, Business Development, Licensing and Custom Product Solutions Europe
2011 - 2014
RESPONSABILITY : - Develop opportunities for sales and margin growth by identifying and executing product sourcing, and channel outsourcing via strategic industry partnerships. - Manage the Covidien Custom Product Solutions division across Europe. - Represent Covidien Europe in large corporate projects (value-segments, M&A, assessment of new business segment). ACHIEVEMENT : - Extended Covidien Custom Product Solutions (CPS) presence into dental, pharma industry, medical devices, rehabilitation and surgical kit-packers market (annual revenue >US20m). - Licensed multiple new products for commercialization by Covidien Medical Supply under private-labels.
2006 - 2010
Head of Direct Sales
2008 - 2010
** Co-Founder / Anteis developed, manufactured and commercialized injectable medical devices made of hyaluronic acid (HA) dedicated to medical aesthetic, surgical ophthalmology and orthopedics ** RESPONSABILITY : - Direct-sales management through affiliates in France and Germany - Evaluate market potential and feasibility towards additional direct market entry (Japan/Brazil) ACHIEVEMENT : - Implement and scale-up dedicated teams across affiliates (25+ people) - Established a JV in Japan, gaining 30% market-share in less than 3 years - Generate >20% of the total company revenue through direct sales
Director, Corporate & Business Development
2006 - 2010
RESPONSABILITY : - Fundraising - Strategic Partnership - B-to-B Franchise ACHIEVEMENT : - US$25m fundraised through 3 leading international VCs - Strategic collaboration with Merz Pharmaceuticals - Double-digit annual growth of the B2B franchise, through large partnerships (Sanofi-Aventis) ** ACQUIRED BY MERZ PHARMA GROUP (TODAY MERZ AESTHETICS) **
2003 - 2006
Sr. Manager, Operations
2003 - 2006
** Co-Founder / Development & commercialization of innovative surgical procedures & products for cataract surgery ** RESPONSABILITY : - Product Development - Clinical & Regulatory Affairs - Supplier Management - Supply-Chain & Customer Service ACHIEVEMENT : - Established new surgical concept for small incision cataract surgery (against induced astigmatism) - Quality System (ISO 13485/9001) & Products Registration in 40+ countries ** ACQUIRED BY CROMA-PHARMA IN 2006 **
2002 - 2003
Sr. Analyst, Strategic Growth
2002 - 2003
** Surgical and contact lens care businesses spun-off from Allergan (2002). Today J&J Vision ** RESPONSABILITY : - Support corporate strategic planning activities - Support M&A and Strategic Partnership initiatives